Mirova’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.4M | Buy |
22,170
+3,226
| +17% | +$3.27M | 0.83% | 35 |
|
|
2025
Q4 | $20.4M | Sell |
18,944
-3,184
| -14% | -$3.04M | 2.94% | 7 |
|
|
2025
Q3 | $16.9M | Sell |
22,128
-6,722
| -23% | -$5M | 2.39% | 10 |
|
|
2025
Q2 | $22.5M | Buy |
28,850
+2,125
| +8% | +$1.65M | 3.17% | 6 |
|
|
2025
Q1 | $22.1M | Buy |
26,725
+1,030
| +4% | +$857K | 3.97% | 6 |
|
|
2024
Q4 | $19.8M | Buy |
25,695
+2,482
| +11% | +$2.06M | 3.42% | 6 |
|
|
2024
Q3 | $20.6M | Sell |
23,213
-2,449
| -10% | -$2.2M | 3.55% | 6 |
|
|
2024
Q2 | $23.2M | Sell |
25,662
-1,770
| -6% | -$1.42M | 4.25% | 6 |
|
|
2024
Q1 | $21.3M | Buy |
27,432
+5,720
| +26% | +$4.07M | 3.78% | 6 |
|
|
2023
Q4 | $12.7M | Sell |
21,712
-2,456
| -10% | -$1.43M | 2.59% | 8 |
|
|
2023
Q3 | $13M | Sell |
24,168
-1,548
| -6% | -$798K | 2.61% | 7 |
|
|
2023
Q2 | $12.1M | Sell |
25,716
-3,182
| -11% | -$1.33M | 2.12% | 9 |
|
|
2023
Q1 | $9.92M | Buy |
28,898
+104
| +0.4% | +$35.1K | 1.43% | 10 |
|
|
2022
Q4 | $10.5M | Buy |
28,794
+1,004
| +4% | +$356K | 1.65% | 7 |
|
|
2022
Q3 | $8.98M | Sell |
27,790
-16,596
| -37% | -$5.26M | 1.51% | 6 |
|
|
2022
Q2 | $14.4M | Buy |
44,386
+2,584
| +6% | +$776K | 2.05% | 7 |
|
|
2022
Q1 | $12M | Buy |
41,802
+13,470
| +48% | +$3.47M | 1.6% | 8 |
|
|
2021
Q4 | $7.83M | Sell |
28,332
-2,756
| -9% | -$699K | 0.94% | 14 |
|
|
2021
Q3 | $7.18M | Sell |
31,088
-2,492
| -7% | -$615K | 0.92% | 15 |
|
|
2021
Q2 | $7.71M | Buy |
33,580
+999
| +3% | +$201K | 0.92% | 14 |
|
|
2021
Q1 | $6.09M | Buy |
32,581
+3,320
| +11% | +$649K | 0.73% | 14 |
|
|
2020
Q4 | $4.94M | Buy |
29,261
+7,049
| +32% | +$1.05M | 0.64% | 17 |
|
|
2020
Q3 | $3.29M | Buy |
22,212
+578
| +3% | +$89.5K | 0.53% | 22 |
|
|
2020
Q2 | $3.55M | Buy |
21,634
+6,213
| +40% | +$954K | 0.82% | 19 |
|
|
2020
Q1 | $2.14M | Buy |
15,421
+7,596
| +97% | +$1.04M | 0.81% | 17 |
|
|
2019
Q4 | $1.03M | Buy |
7,825
+5,341
| +215% | +$619K | 0.36% | 20 |
|
|
2019
Q3 | $278K | Buy |
2,484
+126
| +5% | +$14K | 0.03% | 50 |
|
|
2019
Q2 | $261K | Hold |
2,358
| – | – | 0.02% | 45 |
|
|
2019
Q1 | $306K | Buy |
2,358
+1,466
| +164% | +$178K | 0.17% | 21 |
|
|
2018
Q4 | $103K | Buy |
+892
| New | +$99.6K | 0.05% | 66 |
|
Other funds holding LLY
VCM
VPM
Mirova's LLY Position: Q1 2026 in Review
Mirova increased its Eli Lilly (LLY) stake by 17% in Q1 2026, buying an estimated $3.27M and bringing the position to 22,170 shares worth $20.4M. The position accounts for 0.83% of the portfolio, ranked #35.
Mirova first reported a position in LLY in Q4 2018 and has held it in 30 quarters since. The position peaked at $23.2M in Q2 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Mirova held 22,170 shares of Eli Lilly worth $20.4M as of Q1 2026.
- Mirova bought 3,226 Eli Lilly shares in Q1 2026, an estimated $3.27M.
- Eli Lilly made up 0.83% of Mirova's portfolio in Q1 2026, its #35 holding.
- Mirova first reported a position in Eli Lilly in Q4 2018 and has held it in 30 quarters since.
- Mirova's Eli Lilly position peaked at $23.2M in Q2 2024.
- 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Mirova's 13F filing for Q1 2026, filed 14 May 2026.